Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma

In this multicenter phase I/II trial, the programmed death-ligand 1 (PD-L1) inhibitor atezolizumab and dendritic cells (DCs) loaded with the mesothelioma-associated tumor antigen WT1 will be integrated into platinum/pemetrexed-based first-line chemotherapy for the treatment of epitheloid malignant pleural mesothelioma (MPM). The general objective is to provide the first-in-human experimental demonstration that the combination of platinum/pemetrexed-based chemotherapy with atezolizumab and WT1/DC vaccination is feasible and safe, has clinical activity and enables the induction of mesothelioma-s

Trial Details

NCT ID
NCT05765084
Phase
PHASE1 / PHASE2
Sponsor
University Hospital, Antwerp
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Dendritic cell vaccination
  • Atezolizumab
  • Platinum/pemetrexed based chemotherapy
Locations (sample)
  • Edegem, Antwerp, Belgium|51.15662,4.44504
  • Ghent, Belgium|51.05,3.71667
  • Sint-Niklaas, Belgium|51.16509,4.1437

Key Eligibility Criteria

  • Subjects must meet all the following criteria to be eligible to participate in the study:
  • Signed informed consent
  • Diagnosis with histologically proven epithelioid unresectable MPM (stage I-IV)
  • Age ≥ 18 years at the time of signing informed consent

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →